Avanos Medical, Inc. (AVNS) Tops Q3 EPS by 11c, Affirms FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Avanos Medical, Inc. Announces Third Quarter 2018 Results, Affirms Full-Year Adjusted Diluted Earnings Per Share Guidance
November 6, 2018 7:00 AM ESTALPHARETTA, Ga., Nov. 6, 2018 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2018 results and affirmed its full-year 2018 adjusted diluted earnings per share outlook of $1.75 to $1.90.
"We delivered a solid overall performance in the third quarter, with 10 percent top line growth and adjusted diluted EPS of $0.37, ahead of our expectations. Momentum continued in Interventional Pain and Digestive Health, while Game Ready delivered solid initial performance," said Joe Woody, Avanos chief executive officer.Â
"Our business is well-positioned with Interventional Pain and Chronic Care growing ahead of... More
